Metabolic dysfunction-associated steatotic liver disease and gastroesophageal reflux disease: a mendelian randomization study in European and East Asian populations

被引:0
|
作者
Su, Chen'guang [1 ]
Liao, Zheng [1 ]
Li, Hewen [2 ]
Pei, Yinxuan [1 ]
Wang, Zixiang [1 ]
Li, Jian [1 ]
Liu, Jinlong [1 ,3 ]
机构
[1] Chengde Med Univ, Dept Hepatobiliary Surg, Affiliated Hosp, Chengde, Hebei, Peoples R China
[2] Chengde Med Univ, Dept Minimally Invas Spine Surg, Affiliated Hosp, Chengde, Hebei, Peoples R China
[3] Hebei Key Lab Panvasc Dis, Chengde, Hebei, Peoples R China
关键词
metabolic dysfunction-associated steatotic liver disease; gastroesophageal reflux disease; mendelian randomization; causal effect; genome-wide association studies; ALANINE AMINOTRANSFERASE; RISK-FACTORS; ESOPHAGITIS; PREVALENCE; OBESITY; INSTRUMENTS; SYMPTOMS; BIAS;
D O I
10.3389/fgene.2024.1428334
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background Numerous observational studies have shown a potential association between metabolic dysfunction-associated steatotic liver disease (MASLD) and gastroesophageal reflux disease (GERD). However, causality is unclear. This study utilized genome-wide association study (GWAS) genetic data to explore the causal relationship between MASLD and GERD in European and East Asian populations. Methods This study utilized a bidirectional, two-sample Mendelian randomization (MR) approach. All disease data were obtained from the GWAS database, and single nucleotide polymorphisms strongly associated with exposure were selected as instrumental variables. The inverse variance weighted (IVW) method is primarily utilized to evaluate the causal relationship between exposure and outcome. Finally, sensitivity analyses were performed to ensure the robustness of the results. Results The IVW estimates indicated that non-alcoholic fatty liver disease (NAFLD) (odds ratio (OR) = 1.054, 95% confidence interval (CI), 0.966-1.150, p = 0.236) and percent liver fat (OR = 0.977, 95% CI, 0.937-1.018, p = 0.258) in European population were not linked to a higher risk of GERD. However, GERD in European population was associated with an increased risk of NAFLD (OR = 1.485, 95% CI, 1.274-1.729, p < 0.001) and percent liver fat (OR = 1.244, 95% CI, 1.171-1.321, p < 0.001). In addition, the IVW analysis in East Asian population showed that alanine aminotransferase (ALT) was associated with an increased risk of GERD (OR = 2.305, 95% CI, 1.241-4.281, p = 0.008), whereas aspartate aminotransferase (AST) had no causal effects on GERD risk (OR = 0.973, 95% CI, 0.541-1.749, p = 0.926). Furthermore, the associations between GERD and ALT (OR = 1.007, 95% CI, 0.998-1.015, p = 0.123) or AST (OR = 1.004, 95% CI, 0.997-1.012, p = 0.246) were not significant. After removing outliers, a significant correlation between GERD and ALT was observed (OR = 1.009, 95% CI, 1.001-1.016, p = 0.020). Conclusion There was reverse causality between MASLD and GERD in European population, while there was bidirectional causality between a proxie for MASLD (ALT) and GERD in East Asian population. This study can provide novel insights into cross-ethnic genetic research on MASLD and GERD.
引用
收藏
页数:12
相关论文
共 50 条
  • [11] Druggable genome-wide Mendelian randomization identifies therapeutic targets for metabolic dysfunction-associated steatotic liver disease
    Ma, Xiaohui
    Ding, Li
    Li, Shuo
    Fan, Yu
    Wang, Xin
    Han, Yitong
    Yuan, Hengjie
    Sun, Longhao
    He, Qing
    Liu, Ming
    LIPIDS IN HEALTH AND DISEASE, 2025, 24 (01)
  • [12] From metabolic dysfunction-associated fatty liver disease to metabolic dysfunction-associated steatotic liver disease: Controversy and consensus
    Chen, Li
    WORLD JOURNAL OF HEPATOLOGY, 2023, 15 (12) : 1253 - 1257
  • [13] Nutrients associated with metabolic dysfunction-associated steatotic liver disease
    Jeong, Seogsong
    JOURNAL OF HEPATOLOGY, 2024, 80 (02) : e81 - e82
  • [14] Causal associations of metabolic dysfunction-associated steatotic liver disease with gestational hypertension and preeclampsia: a two-sample Mendelian randomization study
    Zhang, Lu
    Fang, Liang
    Zou, Jiahua
    Zhou, Dong
    Xie, Haonan
    Chen, Aihua
    Wu, Qingming
    HYPERTENSION IN PREGNANCY, 2025, 44 (01)
  • [15] Genetically predicted metabolites mediate the association between immune cells and metabolic dysfunction-associated steatotic liver disease: a mendelian randomization study
    Ye, Dan
    Wang, Jiaofeng
    Shi, Jiaheng
    Ma, Yiming
    Chen, Jie
    Hu, Xiaona
    Bao, Zhijun
    LIPIDS IN HEALTH AND DISEASE, 2024, 23 (01)
  • [16] Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease
    Lee, Hyeok-Hee
    Lee, Han Ah
    Kim, Eun-Jin
    Kim, Hwi Young
    Kim, Hyeon Chang
    Ahn, Sang Hoon
    Lee, Hokyou
    Kim, Seung Up
    GUT, 2024, 73 (03) : 533 - 540
  • [17] Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease
    Noureddin, Nabil
    Copur-Dahi, Nedret
    Loomba, Rohit
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 59 : S41 - S51
  • [18] Psychosocial risks in metabolic dysfunction-associated steatotic liver disease
    Astrom, Hanne
    Takami Lageborn, Christine
    Hagstrom, Hannes
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2025, 19 (03) : 273 - 290
  • [19] Prevalence of metabolic dysfunction-associated steatotic liver disease in the Middle East and North Africa
    Younossi, Zobair M.
    Golabi, Pegah
    Paik, James
    Owrangi, Soroor
    Yilmaz, Yusuf
    El-Kassas, Mohamed
    Alswat, Khalid
    Alqahtani, Saleh A.
    LIVER INTERNATIONAL, 2024, 44 (04) : 1061 - 1070
  • [20] Role of Glucocorticoids in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Polyzos, Stergios A.
    Targher, Giovanni
    CURRENT OBESITY REPORTS, 2024, 13 (02) : 242 - 255